Press Release December 18, 2019

Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of Transformative Treatments for Triplet Repeat Disorders

The Life Sciences team advised Triplet Therapeutics, Inc., on its $49 million Series A financing led by MPM Capital and Pfizer Ventures U.S. LLC, the venture capital arm of Pfizer Inc. (NYSE: PFE). Atlas Venture, which co-founded and seeded Triplet with a $10 million investment, also participated in the Series A alongside Invus, Partners Innovation Fund and Alexandria Venture Investments.

Triplet is a biotechnology company harnessing human genetics to develop treatments for repeat expansion disorders — such as Huntington’s disease, myotonic dystrophy and various spinocerebellar ataxias — at their source. The company will use the Series A funds to progress its first development candidates into IND-enabling studies, as well as to advance natural history studies to inform its clinical development plan and contribute to the scientific understanding of repeat expansion disorders.

The Goodwin team was led by partner Kingsley Taft and counsel Mulon Luo, and included associate Jake Hays, law clerks Pria Narsiman and Wenlan Geng, and paralegals Patricia Robichaud and Coleen Doyle.

For more details, read the press release and articles in FierceBiotech, Xconomy and Chemical & Engineering News.